Hematology
Latest News
Advertisement
Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology
Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.
CME Content
Advertisement
A second biosimilar to Amgen’s Neupogen, which treats neutropenia, has been approved in the United States. The FDA approved Pfizer’s filgrastim-aafi, which will be sold under the brand name Nivestym. Zarxio (filgrastim-sndz) was the first filgrastim biosimilar approved by the FDA in 2015.
The FDA approved the first targeted therapy for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. In addition, FDA also approved a companion diagnostic to be used to detect the specific mutations in the IDH1 gene.
Advertisement
Advertisement
Trending on AJMC
1
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
2
Patients Face New Care Complexities as DTC Options Expand
3
FDA Approves Durvalumab With FLOT Chemotherapy for Resectable Gastric and Gastroesophageal Junction Cancer
4
FDA Approves Gene Therapy Onasemnogene Abeparvovec for Broader SMA Population
5
